Latrovin

Atorvastatin, the active ingredient in Latrovin, is a HMG‑CoA reductase inhibitor (statin) presented as a tablet for oral use. It treats hypercholesterolemia and helps reduce cardiovascular risk in adult patients.

GNH USA supplies Latrovin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin is used to manage disorders of lipid metabolism and to reduce cardiovascular events.

Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. Primary prevention of cardiovascular disease: reduces risk of heart attack and stroke in at‑risk adults. Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established disease. Mixed dyslipidemia: improves overall lipid profile by decreasing LDL and triglycerides while modestly raising HDL.

Common Side Effects: - Muscle aches or weakness - Headache - Nausea - Abdominal pain - Constipation - Elevated liver enzymes

Serious or Rare Side Effects: - Rhabdomyolysis - Severe liver injury - Allergic reactions such as rash or angioedema - Myopathy with marked CK elevation - Acute pancreatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, consider the following precautions.

Liver function monitoring: assess baseline hepatic enzymes and repeat periodically. Muscle symptoms monitoring: discontinue if unexplained muscle pain with CK rise occurs. Drug interactions: review concomitant medications that affect statin metabolism. Pregnancy and lactation: avoid use unless benefits outweigh potential risks. Renal impairment: adjust dose in severe renal dysfunction. Store at room temperature: keep below 25 °C, protect from moisture and light.

Atorvastatin may interact with several medicines; categorize as follows.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin levels. - Gemfibrozil: heightened risk of myopathy. - High‑dose niacin: increased liver toxicity. - Cyclosporine: elevated statin concentrations. - HIV protease inhibitors: greater risk of rhabdomyolysis.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption. - Warfarin: possible enhancement of anticoagulant effect. - Digoxin: potential increase in serum levels. - Beta‑blockers: additive lipid‑lowering effect. - Grapefruit juice: may modestly raise exposure.